MARKET

NVCT

NVCT

Nuvectis Pharma, Inc.
NASDAQ
19.73
+0.50
+2.60%
Opening 12:20 08/14 EDT
OPEN
20.17
PREV CLOSE
19.23
HIGH
20.19
LOW
18.87
VOLUME
47.21K
TURNOVER
--
52 WEEK HIGH
29.28
52 WEEK LOW
5.55
MARKET CAP
642.83M
P/E (TTM)
-15.0829
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NVCT last week (0803-0807)?
Weekly Report · 4d ago
Nuvectis’ NXP800 Ovarian Cancer Trial Terminated: What Investors Should Watch Next
TipRanks · 08/06 16:30
Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and EyePoint Pharmaceuticals (EYPT)
TipRanks · 08/05 19:30
Nuvectis Pharma price target raised to $34 from $22 at Lucid Capital
TipRanks · 08/05 10:11
Nuvectis Pharma’s Heavy Reliance on Haisco Poses Major Operational and Geopolitical Risks
TipRanks · 08/05 06:01
Nuvectis Pharma reports results
Seeking Alpha · 08/04 16:56
Nuvectis Pharma: Buy Rating Reiterated as Late-Stage Pipeline Expands and $39 Price Target Remains Unchanged
TipRanks · 08/04 16:35
Nuvectis Pharma Q2 EPS $(0.30) Misses $(0.26) Estimate
Benzinga · 08/04 12:03
More
About NVCT
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator that has been evaluated in a Phase Ib clinical trial for the treatment of platinum-resistant, ARID1a-mutated ovarian cancer, and it is exploring other development opportunities for NXP800. Chronic activation of GCN2 by NXP800 leads to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is in the Phase Ib program. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers. YES1 is a nonreceptor tyrosine kinase that belongs to the SRC family of kinases and controls multiple cancer signaling pathways.

Webull offers Nuvectis Pharma Inc stock information, including NASDAQ: NVCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVCT stock methods without spending real money on the virtual paper trading platform.